1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Biosimilars Council Commends Nixing ‘Arbitrary’ Interchangeability Designation

The Proposal Was Included In President Biden’s FY2025 Budget Request

 
• By Urtė Fultinavičiūtė

The Biosimilars Council agreed with the US president’s proposal to remove the “unnecessary” designation for biosimilars, which strengthens the ongoing debate over the need for interchangeability.

Person putting files into a bin
• Source: Shutterstock

The Biosimilars Council, a division of US off-patent group the Association for Accessible Medicines, has applauded US president Joe Biden’s latest move to eliminate the biosimilar interchangeability designation in his fiscal year 2025 budget request.

Calling interchangeability an “arbitrary distinction”, the Biosimilars Council said that the US is the “only country in the world with this unnecessary designation for already-approved biosimilars.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Teva Brings In European Trastuzumab With Prestige BioPharma Agreement

 
• By Dean Rudge

Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.

Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod

 
• By Dave Wallace

Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.

Regulatory Recap: ICH To Determine The Future Of Biosimilar Comparative Efficacy Studies

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.

More from Products

Advanz Allies With Pharmathen On Long-Acting Injectable

 
• By Dave Wallace

Advanz Pharma has announced details of a fresh alliance on long-acting injectables with Pharmathen.

Samsung Bioepis Heads For Spin Out To Unlock ‘Hidden Value’

 
• By Dean Rudge

Samsung Biologics will retain solely its significant CDMO business, eliminating a perceived conflict of interest, as it pursues an equity spin-off for its biosimilars business Samsung Bioepis.

Amgen And Samsung Soliris Biosimilars Skirt UK Infringement On Claim Construction

 
• By Dean Rudge

Just days after a court in Canada barred Amgen’s Soliris biosimilar until patent expiry in 2027, a UK High Court has handed a favorable ruling to the California-based firm and Samsung Bioepis, ruling that their products do not infringe a patent shielding the branded treatment for paroxysmal nocturnal hemoglobinuria.